Food Allergy Market to Grow at a Substantial Growth Rate During the Forecast Period (2023-2032) - DelveInsight | Key Companies - Genentech (Xolair/ Omalizumab), DBV Technologies, Novartis, InnoUp Farma, Rho Federal Systems Division

As per DelveInsight, the Food Allergy Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of Food Allergy, entry of novel desensitizing immunotherapies, backed by payer willingness to reimburse, providing affordable coverage to a large addressable population.

DelveInsight's "Food Allergy Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Food Allergy market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Food Allergy drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Food Allergy treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Food Allergy: An Overview
According to the National Institute of Allergy and Infectious Diseases (NIAID), food allergy is an adverse health effect arising from a specific immune response that occurs reproducibly on exposure to a given food.

Food allergens are the parts of food or ingredients within food (usually proteins) recognized by immune cells. When an immune cell binds to a food allergen, a reaction occurs that causes the symptoms of food allergy. These immune system changes fall into two categories: IgE-mediated and Non-IGE-mediated.

The cause of food allergy can be functional genetic variants in the IL-12 receptor b1, Toll-like receptor 9, and thymic stromal lymphopoietin genes, and even IL-4 gene polymorphism have been associated with an increased risk of food sensitization.

While any food can cause an adverse reaction, eight types of food account for about 90% of all reactions: Eggs, milk and dairy, peanuts, tree nuts, fish, shellfish, wheat, wheat, soy, and sesame.

The treatment of food allergy relies on avoidance of the foods to which an individual is allergic, as a therapeutic intervention (tertiary prevention) in patients with food allergy. Unfortunately, severe reactions such as anaphylaxis may occur despite best efforts to avoid them. Epinephrine is the first-line medication for the treatment of anaphylaxis. Additional medications include H1 and H2 antihistamines, corticosteroids, and prostaglandin synthetase inhibitors These drugs are only symptomatic and do not modify the natural course of the disease.

Immunotherapy, may lead to desensitization and reduced risk of severe reactions upon accidental ingestion of an allergen, thus leading to improved quality of life. Aimmune's PALFORZIA, acquired by Nestle in October 2020 is the first FDA-approved product for treating peanut allergy.

Food Allergy Market Key Facts
• In the year 2022, the total prevalent cases of Food allergy were approximately 57,307,000+ cases in the 7MM which is expected to increase by 2032.
• In 2022, approximately 32,885,900+, 16,961,000+, and 7,460,000+ prevalent cases of Food allergy were reported for the United States, EU4 the UK, and Japan respectively. These cases are expected to increase by 2032.
• As per DelveInsight's assessment, in Japan, there were 1,144,500+ and 5,289,500+ cases of Children and Adults respectively in 2022.
• In a study by Gupta et al. (2019), estimated convincing food allergy prevalence among US adults was 10.8%, although 19.0% of adults self-reported a food allergy. The most common allergies were shellfish (2.9%), milk (1.9%), peanut (1.8%), tree nut (1.2%), and fin fish (0.9%). Among food-allergic adults, 51.1% experienced a severe food allergy reaction, 45.3% were allergic to multiple foods, and 48.0% developed food allergies as an adult.

Get a Detailed Overview of the Evolving Food Allergy Market Trends @
https://www.delveinsight.com/report-store/food-allergy-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Food Allergy Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Food Allergy pipeline therapies. It also thoroughly assesses the Food Allergy market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Food Allergy drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Discover How the Food Allergy Market Will Grow by 2032 @
https://www.delveinsight.com/report-store/food-allergy-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Food Allergy Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Food Allergy epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Food Allergy epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.

The Report Covers the Food Allergy Epidemiology, Segmented as -
• Prevalent Cases of Food Allergy in the 7MM [2019-2032]
• Etiology-specific Prevalent Cases of Food Allergy in the 7MM [2019-2032]
• Age-specific Prevalent Cases of Food Allergy in the 7MM [2019-2032]

Get Key Insights Into the Evolving Food Allergy Epidemiology Trends @
https://www.delveinsight.com/sample-request/food-allergy-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Food Allergy Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Food Allergy market or expected to be launched during the study period. The analysis covers the Food Allergy market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Food Allergy drugs based on their sale and market share.

The report also covers the Food Allergy pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Food Allergy companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Food Allergy Therapeutics Analysis
The only proven medication therapy against a food allergy is the strict elimination of the offending food allergen from the diet. The primary care of treatment, including antihistamines, injectable epinephrine, and immunotherapies is prescribed to patients with mild, and moderate to severe cases of Food Allergy. Injectable epinephrine is the drug of choice for the initial management of a food-induced anaphylactic reaction.

To further improve the treatment outlook, several prominent pharma and biotech companies are actively engaged in developing therapies for Food Allergies, a significant health concern affecting millions worldwide. Among these key players, DBV Technologies stands out for advancing its Food Allergies drug candidates to the most advanced stage of clinical development, specifically preregistration. This milestone highlights the collective commitment within the pharmaceutical industry to address the complexities of food allergies and underscores DBV Technologies' dedication to bringing innovative treatments to individuals affected by this condition.

On February 16, 2024, the FDA approved Xolair® (omalizumab) for the reduction of allergic reactions, including anaphylaxis, that may occur with accidental exposure to one or more foods in adult and pediatric patients aged 1 year and older with IgE-mediated food allergy.

Food Allergy Companies Actively Working in the Therapeutics Market Include
• Novartis Pharmaceuticals
• DBV Technologies
• InnoUp Farma S.L.
• Genentech, Inc.
• Novartis Pharmaceuticals
• Rho Federal Systems Division
And Many Others

Emerging and Marketed Food Allergy Therapies Covered in the Report Include:
• Ligelizumab (Novartis Pharmaceuticals),
• Viaskin Peanut (DBV Technologies),
• INP20 (InnoUp Farma S.L.),
• Omalizumab (Genentech, Inc. /Novartis Pharmaceuticals/Rho Federal Systems Division, Inc.)
• Dupilumab (Regeneron Pharmaceuticals)
• ADP101 (Alladapt Immunotherapeutics)
And Many Others

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/food-allergy-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Food Allergy Competitive Intelligence Analysis
4. Food Allergy Market Overview at a Glance
5. Food Allergy Disease Background and Overview
6. Food Allergy Patient Journey
7. Food Allergy Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Food Allergy Treatment Algorithm, Current Treatment, and Medical Practices
9. Food Allergy Unmet Needs
10. Key Endpoints of Food Allergy Treatment
11. Food Allergy Marketed Therapies
12. Food Allergy Emerging Drugs and Latest Therapeutic Advances
13. Food Allergy Seven Major Market Analysis
14. Attribute Analysis
15. Food Allergy Market Outlook (In US, EU5, and Japan)
16. Food Allergy Companies Active in the Market
17. Food Allergy Access and Reimbursement Overview
18. KOL Views on the Food Allergy Market
19. Food Allergy Market Drivers
20. Food Allergy Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/food-allergy-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.